



Medicine Supply Notification

MSN/2026/038

Beclometasone dipropionate (Clenil Modulite®) 50micrograms/dose and 250 micrograms/dose inhalers

Tier 2 – medium impact*

Date of issue: 25/08/2026

Link: [Medicines Supply Tool](#)

Summary

- Beclometasone dipropionate (Clenil Modulite®) 50micrograms/dose and 250micrograms/dose inhalers will be discontinued at the end of November 2026.
- Beclometasone dipropionate (Soprobec®) 50micrograms/dose and 250micrograms/dose inhalers remain available and can support increased demand.
- Beclometasone dipropionate (Clenil Modulite®) 100micrograms/dose inhaler remains available and can support an increased demand for patients where appropriate (see below).
- Beclometasone dipropionate CFC-free pressurised metered dose inhalers (pMDIs), Qvar® and Kelhale®, remain available for patients where appropriate (see below).

Actions Required

Prescribers should:

- not initiate any new patients on Clenil Modulite® 50micrograms/dose or 250micrograms/dose inhalers;
- review patients currently prescribed Clenil Modulite® 50micrograms/dose and 250microgram/dose inhalers to determine whether this remains the most appropriate therapy or if their treatment regimen should be amended in line with current [NICE/BTS/SIGN guidance](#) recommending combination inhalers that deliver AIR and MART therapy;
- consider prescribing Clenil Modulite® 100micrograms/dose inhalers for patients using 2 puffs of Clenil Modulite® 50micrograms/dose to deliver 100micrograms per dose, ensuring the patient is counselled on this change;
- consider prescribing Soprobec® 50micrograms/dose or 250micrograms/dose inhaler, ensuring that the patient:
 - can use an inhaler **without a dose counter**;
 - is counselled that the although the inhaler differs in colour, it delivers the same drug, and dosing remains the same;
 - is provided with training to ensure correct use of the inhaler; and
 - is given advice on how to keep track of doses used to ensure adherence to treatment as well as timely requests for repeat prescriptions (see Supporting Information below).
- consider prescribing on a case-by-case basis, Qvar® inhalers for patients aged 5 and above or Kelhale® inhalers for adults who can benefit from a dose counter (see NOTE below).

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

If the above options are not considered appropriate, refer to local/national guidance for selection of another management option or seek Advice and Guidance (A&G) from specialists.

Supporting information

Clinical Information

Clenil Modulite® and Soprobec® are pressurised metered dose inhalers (pMDI) delivering the same dose of beclometasone. They are licensed for the prophylactic management of asthma. The Volumatic™ spacer device is compatible with both inhalers.

Unlike Clenil Modulite®, Soprobec® inhalers lack a dose counter. [NICE/BTS/SIGN guidance](#) on asthma recommends that choice of inhaler should be based on an assessment of correct technique, patient preference, lowest environmental impact among suitable devices, and the presence of an integral dose counter. For inhalers without a dose counter, patients should be advised on how to calculate how many days the inhaler should last and mark on a calendar or set a reminder to alert them at least a week before it is due to run out. They should also document how many puffs are being used. There are mobile phone apps available to help keep track of inhaler usage.

[NICE/BTS/SIGN guidance](#) recommends that the initial management for newly diagnosed asthma in people aged 12 years and over should now be with either:

- low-dose inhaled corticosteroid/formoterol combination to be taken as-needed (Anti-inflammatory reliever [AIR] therapy) or
- low-dose maintenance and reliever (MART) therapy for patients with highly symptomatic asthma (e.g. regular nocturnal waking) or with a severe exacerbation, which can be stepped down to as-needed AIR therapy, if asthma is controlled.

Note: The beclometasone dipropionate CFC-free pMDIs, Qvar® and Kelhale®, are not interchangeable with Clenil Modulite® as they contain extra-fine particles and are approximately twice as potent as Clenil Modulite®. All beclometasone dipropionate CFC-free pMDIs should be prescribed by brand name.

Links to further information

- [BNF beclometasone dipropionate](#)
- [BTS/NICE/SIGN Joint Guideline on Asthma: diagnosis, monitoring and chronic asthma management](#)
- [Clenil Modulite® inhaler SmPC](#)
- [Medicines for Children- Asthma article 5: Make sure you're not running on empty!](#)
- [Soprobec® inhaler SmPC](#)
- [Kelhale® inhalers SmPC](#)
- [Qvar® inhalers SmPC](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.